Plus: More discussion of the Great British Bake Off than you might expect
What's in store for biotech VCs next year? Will Pfizer's new R&D head do enough to appease investors? And should Adam get a position under the new Food and Drug Administration commissioner?
We discuss all this and more on this week's episode of "The Readout LOUD." Atlas Venture partner Bruce Booth joins us to discuss his annual year in review report, the influence of China, and what the new Trump administration might mean for innovation. Adam and Allison also recap the latest news in the life sciences, including a new science chief at Pfizer, a new job for Ned Sharpless, and the ongoing presidential appointments. Listen Now To read up on Pfizer's new R&D head, Chris Boshoff, go here; to learn more about Sharpless' new firm Jupiter Bioventures, go here; for more information on the top contenders for FDA commissioner, go here; and for details about how biotechs are working with Chinese companies, go here. Be sure to sign up for "The Readout LOUD" on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts. Subscribe to the podcast to never miss an episode Visit the archive to see past episodes |
|
| STAT, 1 Exchange Place, Boston, MA | ©2024, All Rights Reserved. | |
|
No comments